Abstract
Botulinum toxin (BT) therapy is an established treatment of spasticity due to stroke. For multiple sclerosis (MS) spasticity this is not the case. IAB-Interdisciplinary Working Group for Movement Disorders formed a task force to explore the use of BT therapy for treatment of MS spasticity. A formalised PubMed literature search produced 55 publications (3 randomised controlled trials, 3 interventional studies, 11 observational studies, 2 case studies, 35 reviews, 1 guideline) all unanimously favouring the use of BT therapy for MS spasticity. There is no reason to believe that BT should be less effective and safe in MS spasticity than it is in stroke spasticity. Recommendations include an update of the current prevalence of MS spasticity and its clinical features according to classifications used in movement disorders. Immunological data on MS patients already treated should be analysed with respect to frequencies of MS relapses and BT antibody formation. Registration authorities should expand registration of BT therapy for spasticity regardless of its aetiology. MS specialists should consider BT therapy for symptomatic treatment of spasticity.
| Original language | English |
|---|---|
| Pages (from-to) | 112-120 |
| Number of pages | 9 |
| Journal | Journal of Neurology |
| Volume | 264 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1 Jan 2017 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Neurology
- Clinical Neurology
Cite this
}
Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. / Dressler, Dirk; Bhidayasiri, Roongroj; Bohlega, Saeed; Chahidi, Abderrahmane; Chung, Tae Mo; Ebke, Markus; Jacinto, L. Jorge; Kaji, Ryuji; Koçer, Serdar; Kanovsky, Petr; Micheli, Federico; Orlova, Olga; Paus, Sebastian; Pirtosek, Zvezdan; Relja, Maja; Rosales, Raymond L.; Sagástegui-Rodríguez, José Alberto; Schoenle, Paul W.; Shahidi, Gholam Ali; Timerbaeva, Sofia; Walter, Uwe; Saberi, Fereshte Adib.
In: Journal of Neurology, Vol. 264, No. 1, 01.01.2017, p. 112-120.Research output: Contribution to journal › Article
TY - JOUR
T1 - Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force
AU - Dressler, Dirk
AU - Bhidayasiri, Roongroj
AU - Bohlega, Saeed
AU - Chahidi, Abderrahmane
AU - Chung, Tae Mo
AU - Ebke, Markus
AU - Jacinto, L. Jorge
AU - Kaji, Ryuji
AU - Koçer, Serdar
AU - Kanovsky, Petr
AU - Micheli, Federico
AU - Orlova, Olga
AU - Paus, Sebastian
AU - Pirtosek, Zvezdan
AU - Relja, Maja
AU - Rosales, Raymond L.
AU - Sagástegui-Rodríguez, José Alberto
AU - Schoenle, Paul W.
AU - Shahidi, Gholam Ali
AU - Timerbaeva, Sofia
AU - Walter, Uwe
AU - Saberi, Fereshte Adib
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Botulinum toxin (BT) therapy is an established treatment of spasticity due to stroke. For multiple sclerosis (MS) spasticity this is not the case. IAB-Interdisciplinary Working Group for Movement Disorders formed a task force to explore the use of BT therapy for treatment of MS spasticity. A formalised PubMed literature search produced 55 publications (3 randomised controlled trials, 3 interventional studies, 11 observational studies, 2 case studies, 35 reviews, 1 guideline) all unanimously favouring the use of BT therapy for MS spasticity. There is no reason to believe that BT should be less effective and safe in MS spasticity than it is in stroke spasticity. Recommendations include an update of the current prevalence of MS spasticity and its clinical features according to classifications used in movement disorders. Immunological data on MS patients already treated should be analysed with respect to frequencies of MS relapses and BT antibody formation. Registration authorities should expand registration of BT therapy for spasticity regardless of its aetiology. MS specialists should consider BT therapy for symptomatic treatment of spasticity.
AB - Botulinum toxin (BT) therapy is an established treatment of spasticity due to stroke. For multiple sclerosis (MS) spasticity this is not the case. IAB-Interdisciplinary Working Group for Movement Disorders formed a task force to explore the use of BT therapy for treatment of MS spasticity. A formalised PubMed literature search produced 55 publications (3 randomised controlled trials, 3 interventional studies, 11 observational studies, 2 case studies, 35 reviews, 1 guideline) all unanimously favouring the use of BT therapy for MS spasticity. There is no reason to believe that BT should be less effective and safe in MS spasticity than it is in stroke spasticity. Recommendations include an update of the current prevalence of MS spasticity and its clinical features according to classifications used in movement disorders. Immunological data on MS patients already treated should be analysed with respect to frequencies of MS relapses and BT antibody formation. Registration authorities should expand registration of BT therapy for spasticity regardless of its aetiology. MS specialists should consider BT therapy for symptomatic treatment of spasticity.
UR - http://www.scopus.com/inward/record.url?scp=84992700470&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992700470&partnerID=8YFLogxK
U2 - 10.1007/s00415-016-8304-z
DO - 10.1007/s00415-016-8304-z
M3 - Article
VL - 264
SP - 112
EP - 120
JO - Journal of Neurology
JF - Journal of Neurology
SN - 0340-5354
IS - 1
ER -